| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 138, Issue 10 3247-3253, Copyright © 1987 by American Association of Immunologists
ARTICLES |
D Wofsy and WE Seaman
Murine lupus in NZB/NZW F1 (B/W) mice can be prevented by weekly treatment with monoclonal antibodies (MAb) to L3T4 (on "helper/inducer" T cells) if treatment is begun prior to the onset of clinical illness. To determine whether anti-L3T4 could reverse as well as prevent murine lupus, we monitored a cohort of 30 B/W females until age 7 mo, when severe autoimmune disease was established, and then we examined the effects of weekly treatment with MAb to L3T4. The rate of target cell clearance by MAb was considerably slower in old B/W mice than it was in young B/W mice or in normal (BALB/c and C57BL/6) mice. Nonetheless, treatment with anti-L3T4 depleted 90% of circulating L3T4+ cells over 3 mo. In treated mice, the concentration of anti-DNA antibodies fell by 80%, renal insufficiency was reversed, and 1 yr survival was 75% compared to 17% in controls. These findings indicate that L3T4+ cells play an important role in perpetuating murine lupus in B/W mice even after severe disease is present. Because the L3T4 antigen in mice is homologous to the Leu-3/T4 (CD4) antigen in humans, these findings suggest that treatment with CD4 MAb may be effective in people with systemic lupus erythematosus.
This article has been cited by other articles:
|
|
 |
|
  E. Beger, B. Deocharan, M. Edelman, B. Erblich, Y. Gu, and C. Putterman A Peptide DNA Surrogate Accelerates Autoimmune Manifestations and Nephritis in Lupus-Prone Mice J. Immunol., April 1, 2002; 168(7): 3617 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Lawson, S. I. Koundouris, M. Barnhouse, W. Dummer, R. Baccala, D. H. Kono, and A. N. Theofilopoulos The Role of {alpha}{beta}+ T Cells and Homeostatic T Cell Proliferation in Y-Chromosome-Associated Murine Lupus J. Immunol., August 15, 2001; 167(4): 2354 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D A Horwitz Peripheral blood CD4/ T cells in systemic lupus erythematosus Lupus, May 1, 2001; 10(5): 319 - 320. [PDF]
|
|
|
|
|
|
B Griffiths and P Emery The treatment of lupus with cyclosporin A Lupus, March 1, 2001; 10(3): 165 - 170. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Sieling, S. A. Porcelli, B. T. Duong, F. Spada, B. R. Bloom, B. Diamond, and B. H. Hahn Human Double-Negative T Cells in Systemic Lupus Erythematosus Provide Help for IgG and Are Restricted by CD1c J. Immunol., November 1, 2000; 165(9): 5338 - 5344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Stoll and J. Gavalchin Systemic lupus erythematosus--messages from experimental models Rheumatology, January 1, 2000; 39(1): 18 - 27. [Full Text] [PDF]
|
|
|
|
|
|
B. Liang, R. J. Gee, M. J. Kashgarian, A. H. Sharpe, and M. J. Mamula B7 Costimulation in the Development of Lupus: Autoimmunity Arises Either in the Absence of B7.1/B7.2 or in the Presence of Anti-B7.1/B7.2 Blocking Antibodies J. Immunol., August 15, 1999; 163(4): 2322 - 2329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Hahn Antibodies to DNA N. Engl. J. Med., May 7, 1998; 338(19): 1359 - 1368. [Full Text] [PDF]
|
|
|
|
|
|
D.A. Isenberg, C.T. Ravirajan, A. Rahman, and J. Kalsi The role of antibodies to DNA in systemic lupus erythematosus A review and introduction to an international workshop on DNA antibodies held in London, May 1996 Lupus, January 1, 1997; 6(3): 290 - 304. [PDF]
|
|
|
|
 |
|
 J. Shizuru, C Taylor-Edwards, B. Banks, A. Gregory, and C. Fathman Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes Science, April 29, 1988; 240(4852): 659 - 662. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
